Management of Venous Leakage in Erectile Dysfunction

Introduction to Treatment Options

The American Urological Association recommends that the management of venous leakage in erectile dysfunction should start with phosphodiesterase type 5 inhibitors (sildenafil, vardenafil, tadalafil) as first-line therapy, followed by vacuum constriction devices if phosphodiesterase type 5 inhibitors fail, reserving surgical options only for highly selected young patients without cardiovascular risk factors 1, 2

Phosphodiesterase type 5 inhibitors are the recommended oral first-line therapy for erectile dysfunction, including cases with venous leakage, with a strength of evidence level of 1 1, 2, 3
These medications work by delaying the degradation of cGMP, producing relaxation of smooth muscle in the corpus cavernosum and improving blood flow 3
The European Association of Urology recommends initiating treatment with tadalafil 5 mg daily or 10-20 mg as needed, or sildenafil 50-100 mg as needed 3
Before initiating treatment, a cardiovascular risk assessment should be performed and the patient categorized as low, intermediate, or high risk 4, 3
High-risk cardiovascular patients should be cardiologically stabilized before considering sexual activity or treatment for erectile dysfunction 4, 3

If phosphodiesterase type 5 inhibitors fail, vacuum constriction devices are the next recommended option, with a success rate of 69% in patients with confirmed venous leakage 1, 2

Intracavernous alprostadil (10-40 mcg) is an effective option when oral treatments and vacuum devices fail, with a mean effective dose of 13.8-25.9 mcg and 73-76% of patients achieving erections with adequate axial rigidity 1, 2

The American Urological Association recommends that venous surgery should be reserved exclusively for young patients with primary venous leakage, without diabetes, without cardiovascular risk factors, and with a normal penile arterial system 1, 2

Concomitant use of nitrates is an absolute contraindication for phosphodiesterase type 5 inhibitors, due to the risk of hypotension and myocardial infarction 3
Patients with unstable or refractory angina, uncontrolled hypertension, heart failure class II or higher, or recent myocardial infarction or stroke should not receive phosphodiesterase type 5 inhibitors 4

The European Association of Urology recommends reviewing current medications that may contribute to erectile dysfunction and considering alternatives, as well as optimizing glycemic control in diabetic patients and managing cardiovascular risk factors 3
Lifestyle modifications, such as weight loss in obese patients, smoking cessation, and regular exercise, should also be considered 2, 4